Skip to main content
Erschienen in: Tumor Biology 2/2013

01.04.2013 | Research Article

BMI, apolipoprotein B/apolipoprotein A-I ratio, and insulin resistance in patients with prolactinomas: a pilot study in a Chinese cohort

verfasst von: Xiao-Bing Jiang, Dong-Sheng He, Zhi-Gang Mao, Xiang Fan, Ni Lei, Bin Hu, Bing-Bing Song, Yong-Hong Zhu, Hai-Jun Wang

Erschienen in: Tumor Biology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Deranged metabolic profiles and insulin resistance (IR) have been documented in patients with prolactinomas. Few data are yet available on the apolipoprotein (apo) B/apoA-I ratio and its relationship with IR in patients with prolactinomas. This study was aimed to evaluate the level of apoB/apoA-I ratio and its association with IR in a Chinese subgroup with prolactinomas. Twenty-three prolactinoma patients and 20 healthy controls were enrolled in this study. The clinical anthropometric parameters and laboratory evaluation were collected. Insulin sensitivity was estimated using homeostatic model assessment [homeostasis model assessment of insulin resistance (HOMA-IR)]. Waist circumference and body weight index (BMI) were significantly higher in patients with prolactinomas than those in the controls (p < 0.05). Meanwhile, the prevalence of general and abdominal obesity seemed more pronounced in male patients compared to that in healthy subjects (57.14 vs. 0 % and 71.43 vs. 16.7 %, respectively). Furthermore, fasting glucose, insulin, HOMA-IR, triglyceride, and apoB/apoA-I ratio were also significantly higher in prolactinoma patients, but with lower level of apoA-I (p < 0.05). Univariate regression analysis revealed that prolactin, waist circumference, BMI, and presence of hypogonadism were significantly associated with IR (p < 0.05). However, only BMI [odds ratio (OR) = 1.937, 95 % confidence interval (CI) 1.112–3.375, p = 0.02] and prolactin (OR = 5.173, 95 % CI 1.073–24.94, p = 0.041) were shown to be independent predictors for the presence of IR in multivariate logistic analysis. This study confirmed the altered metabolic profile, including body weight gain, IR, disordered lipids, and apolipoproteins in prolactinoma patients. Prolactin and BMI were independently associated with IR. The effect of apoB/apoA-I ratio on IR is warranted to be determined in further studies.
Literatur
1.
Zurück zum Zitat Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of liege, Belgium. J Clin Endocrinol Metab. 2006;91:4769–75.PubMedCrossRef Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of liege, Belgium. J Clin Endocrinol Metab. 2006;91:4769–75.PubMedCrossRef
2.
Zurück zum Zitat Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:273–88.PubMedCrossRef Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:273–88.PubMedCrossRef
4.
Zurück zum Zitat dos Santos Silva CM, Barbosa FR, Lima GA, et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring). 2011;19:800–5.CrossRef dos Santos Silva CM, Barbosa FR, Lima GA, et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring). 2011;19:800–5.CrossRef
5.
Zurück zum Zitat Serri O, Li L, Mamputu JC, et al. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf). 2006;64:366–70. Serri O, Li L, Mamputu JC, et al. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf). 2006;64:366–70.
6.
Zurück zum Zitat Berinder K, Nystrom T, Hoybye C, et al. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary. 2011;14:199–207.PubMedCrossRef Berinder K, Nystrom T, Hoybye C, et al. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary. 2011;14:199–207.PubMedCrossRef
7.
Zurück zum Zitat Johnston DG, Alberti KG, Nattrass M, et al. Hyperinsulinaemia in hyperprolactinaemic women. Clin Endocrinol (Oxf). 1980;13:361–8.CrossRef Johnston DG, Alberti KG, Nattrass M, et al. Hyperinsulinaemia in hyperprolactinaemic women. Clin Endocrinol (Oxf). 1980;13:361–8.CrossRef
8.
Zurück zum Zitat Ben-Jonathan N, Hugo ER, Brandebourg TD, et al. Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab. 2006;17:110–6.PubMedCrossRef Ben-Jonathan N, Hugo ER, Brandebourg TD, et al. Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab. 2006;17:110–6.PubMedCrossRef
9.
Zurück zum Zitat Park S, Kim DS, Daily JW, et al. Serum prolactin concentrations determine whether they improve or impair beta-cell function and insulin sensitivity in diabetic rats. Diabetes Metab Res Rev. 2011;27:564–74.PubMedCrossRef Park S, Kim DS, Daily JW, et al. Serum prolactin concentrations determine whether they improve or impair beta-cell function and insulin sensitivity in diabetic rats. Diabetes Metab Res Rev. 2011;27:564–74.PubMedCrossRef
10.
Zurück zum Zitat Bahceci M, Tuzcu A, Bahceci S, et al. Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome? J Endocrinol Invest. 2003;26:655–9.PubMed Bahceci M, Tuzcu A, Bahceci S, et al. Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome? J Endocrinol Invest. 2003;26:655–9.PubMed
11.
Zurück zum Zitat Doumatey AP, Lashley KS, Huang H, et al. Relationships among obesity, inflammation, and insulin resistance in African Americans and West Africans. Obesity (Silver Spring). 2010;18:598–603.CrossRef Doumatey AP, Lashley KS, Huang H, et al. Relationships among obesity, inflammation, and insulin resistance in African Americans and West Africans. Obesity (Silver Spring). 2010;18:598–603.CrossRef
12.
Zurück zum Zitat Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy—a review of the evidence. J Intern Med. 2006;259:493–519.PubMedCrossRef Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy—a review of the evidence. J Intern Med. 2006;259:493–519.PubMedCrossRef
13.
Zurück zum Zitat Enkhmaa B, Anuurad E, Zhang Z, et al. Usefulness of apolipoprotein B/apolipoprotein A-I ratio to predict coronary artery disease independent of the metabolic syndrome in African Americans. Am J Cardiol. 2010;106:1264–9.PubMedCrossRef Enkhmaa B, Anuurad E, Zhang Z, et al. Usefulness of apolipoprotein B/apolipoprotein A-I ratio to predict coronary artery disease independent of the metabolic syndrome in African Americans. Am J Cardiol. 2010;106:1264–9.PubMedCrossRef
14.
Zurück zum Zitat Dahlen EM, Lanne T, Engvall J, et al. Carotid intima-media thickness and apolipoprotein B/apolipoprotein A-I ratio in middle-aged patients with type 2 diabetes. Diabet Med. 2009;26:384–90.PubMedCrossRef Dahlen EM, Lanne T, Engvall J, et al. Carotid intima-media thickness and apolipoprotein B/apolipoprotein A-I ratio in middle-aged patients with type 2 diabetes. Diabet Med. 2009;26:384–90.PubMedCrossRef
15.
Zurück zum Zitat Reuwer AQ, van Eijk M, Houttuijn-Bloemendaal FM, et al. The prolactin receptor is expressed in macrophages within human carotid atherosclerotic plaques: a role for prolactin in atherogenesis? J Endocrinol. 2011;208:107–17.PubMedCrossRef Reuwer AQ, van Eijk M, Houttuijn-Bloemendaal FM, et al. The prolactin receptor is expressed in macrophages within human carotid atherosclerotic plaques: a role for prolactin in atherogenesis? J Endocrinol. 2011;208:107–17.PubMedCrossRef
16.
Zurück zum Zitat Carnevale SG, Pedrazzoli R, Onolfo S, et al. ApoB/apoA-I ratio is better than LDL-C in detecting cardiovascular risk. Nutr Metab Cardiovasc Dis. 2011;21:406–11.CrossRef Carnevale SG, Pedrazzoli R, Onolfo S, et al. ApoB/apoA-I ratio is better than LDL-C in detecting cardiovascular risk. Nutr Metab Cardiovasc Dis. 2011;21:406–11.CrossRef
17.
Zurück zum Zitat Sierra-Johnson J, Romero-Corral A, Somers VK, et al. ApoB/apoA-I ratio: an independent predictor of insulin resistance in us non-diabetic subjects. Eur Heart J. 2007;28:2637–43.PubMedCrossRef Sierra-Johnson J, Romero-Corral A, Somers VK, et al. ApoB/apoA-I ratio: an independent predictor of insulin resistance in us non-diabetic subjects. Eur Heart J. 2007;28:2637–43.PubMedCrossRef
18.
Zurück zum Zitat Kelishadi R, Cook SR, Amra B, et al. Factors associated with insulin resistance and non-alcoholic fatty liver disease among youths. Atherosclerosis. 2009;204:538–43.PubMedCrossRef Kelishadi R, Cook SR, Amra B, et al. Factors associated with insulin resistance and non-alcoholic fatty liver disease among youths. Atherosclerosis. 2009;204:538–43.PubMedCrossRef
19.
Zurück zum Zitat de Assunção Alves Rodrigues LF, Campos SM, Miranda PA, et al. Prolactinoma: a condition associated with hypoadiponectinemia. Horm Metab Res. 2012;44:832–8.PubMedCrossRef de Assunção Alves Rodrigues LF, Campos SM, Miranda PA, et al. Prolactinoma: a condition associated with hypoadiponectinemia. Horm Metab Res. 2012;44:832–8.PubMedCrossRef
20.
Zurück zum Zitat Alberti KG, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366:1059–62.PubMedCrossRef Alberti KG, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366:1059–62.PubMedCrossRef
21.
Zurück zum Zitat WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–63.CrossRef WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–63.CrossRef
22.
Zurück zum Zitat Schmid C, Goede DL, Hauser RS, et al. Increased prevalence of high body mass index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Wkly. 2006;136:254–8.PubMed Schmid C, Goede DL, Hauser RS, et al. Increased prevalence of high body mass index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Wkly. 2006;136:254–8.PubMed
23.
Zurück zum Zitat Doknic M, Pekic S, Zarkovic M, et al. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol. 2002;147:77–84.PubMedCrossRef Doknic M, Pekic S, Zarkovic M, et al. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol. 2002;147:77–84.PubMedCrossRef
24.
Zurück zum Zitat Xi B, Liang Y, He T, et al. Secular trends in the prevalence of general and abdominal obesity among Chinese adults, 1993–2009. Obes Rev. 2012;13:287–96.PubMedCrossRef Xi B, Liang Y, He T, et al. Secular trends in the prevalence of general and abdominal obesity among Chinese adults, 1993–2009. Obes Rev. 2012;13:287–96.PubMedCrossRef
Metadaten
Titel
BMI, apolipoprotein B/apolipoprotein A-I ratio, and insulin resistance in patients with prolactinomas: a pilot study in a Chinese cohort
verfasst von
Xiao-Bing Jiang
Dong-Sheng He
Zhi-Gang Mao
Xiang Fan
Ni Lei
Bin Hu
Bing-Bing Song
Yong-Hong Zhu
Hai-Jun Wang
Publikationsdatum
01.04.2013
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 2/2013
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0660-z

Weitere Artikel der Ausgabe 2/2013

Tumor Biology 2/2013 Zur Ausgabe

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.